SLS — SELLAS Life Sciences Group, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1390478 ·
Last close
$11.65
Market Cap
$2.35B
52W High
$15.88
52W Low
$1.39
ADV30
6,047,144
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -10,629,000 | -9,605,000 | 145,382,000 | 138,343,000 | 7,726,000 |
| Mar 2026 | 0 | — | -9,252,000 | -8,407,000 | 114,177,000 | 107,097,000 | 6,765,000 |
| Dec 2025 | 0 | — | -8,255,000 | -7,658,000 | 78,345,000 | 71,793,000 | 7,474,000 |
| Sep 2025 | 0 | — | -7,083,000 | -6,791,000 | 51,555,000 | 44,320,000 | 5,925,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,165,000
Investing CF
$0
Financing CF
$106,865,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.25
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-283,395,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-31,463,000
Pretax Income TTM
$-29,457,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,274,000 | -26,863,000 | 78,345,000 | 7,474,000 | 70,871,000 | -28,389,000 |
| Dec 2024 | 0 | -31,513,000 | -30,881,000 | 19,432,000 | 9,967,000 | 9,465,000 | -35,402,000 |
| Dec 2023 | 0 | -37,869,000 | -37,340,000 | 6,219,000 | 14,195,000 | -7,976,000 | -31,410,000 |
| Dec 2022 | 1,000,000 | -31,950,000 | -41,301,000 | 20,943,000 | 16,092,000 | 4,851,000 | -23,809,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$33,712,000
NetIncome TTM
$-29,457,000
OpCashFlow TTM
—
Assets (Latest)
$114,177,000
Forward EPS
$-0.10
Max Pain — expiry 2026-10-16
max pain strike: $12.00 · spot: $11.65 · call oi: 74,136 · put oi: 88,107
Expected Move to 2026-10-16:
±$1.38
(11.80%) —
implied range
$10.28 –
$13.03
· ATM straddle on $11.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HRMY | Harmony Biosciences Holdings, Inc. | $2.35B | $40.28 | — |
| IRON | Disc Medicine, Inc. | $2.38B | $62.06 | — |
| NRIX | Nurix Therapeutics, Inc. | $2.32B | $22.35 | — |
| PBH | Prestige Consumer Healthcare Inc. | $2.28B | $48.23 | — |
| BHC | Bausch Health Companies Inc. | $2.26B | $6.04 | — |
News headlines (Yahoo Finance, 1h cache)
SLS Stock’s 2-Week Rally Loses Steam: Retail Sees ‘Peanut Prices’ As Fresh AML Study Fuels Regal Hopes
2026-10-08 03:54 · Yahoo
Despite Heavy Hedge Fund Support, Why Sellas Life Sciences (SLS) Fell 16.6% in Q3
2026-10-01 03:45 · Yahoo
Can SELLAS Life Sciences (SLS) Turn Early CDK9 Pancreatic Data Into a Durable Oncology Edge?
2026-10-01 02:08 · Yahoo
SELLAS Life Sciences Group (SLS) Stock May Be Trading At A Premium On Fresh Pancreatic Cancer Data
2026-09-30 15:08 · Yahoo
SELLAS Life Sciences Group (SLS) Could Be Fully Priced After Fresh SLS009 Pancreatic Data
2026-09-30 08:09 · Yahoo
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
2026-09-30 03:47 · Yahoo
SLS Stock Slips 3% As Pancreatic Cancer Lab Data Leave REGAL Wait Unanswered
2026-09-25 20:37 · Yahoo
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
2026-09-25 17:00 · Yahoo
SLS Stock Slips Overnight Ahead Of Pancreatic Cancer Conference — Retail Looks For Clues To SLS009’s Next Trial
2026-09-24 04:59 · Yahoo
Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next
2026-09-21 04:37 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.